Form 4: Phibro CEO Plans 2025 Stock Sales Under 10b5-1 Plan

Phibro Animal Health Corp's President and CEO, Jack Bendheim, along with BFI Co., LLC, reported planned conversions of Class B to Class A common stock and subsequent sales in November 2025 under a pre-arranged 10b5-1 trading plan.

Summary

• Jack Bendheim, President and CEO, Director, and 10% Owner of Phibro Animal Health Corp (PAHC), along with BFI Co., LLC, filed a Form 4 reporting planned transactions.
• On November 14, 2025, 55,000 shares of Class B Common Stock are planned to be converted into 55,000 shares of Class A Common Stock at a price of $0.
• Following the conversion, BFI Co., LLC's indirect beneficial ownership of Class A Common Stock is planned to increase by 55,000 shares.
• On November 17, 2025, BFI Co., LLC plans to sell 5,280 shares of Class A Common Stock at a weighted average price of $44.5557, with prices ranging from $44.24 to $44.96.
• On November 18, 2025, BFI Co., LLC plans to sell 5,260 shares of Class A Common Stock at a weighted average price of $43.8196, with prices ranging from $43.27 to $44.26.
• Also on November 18, 2025, BFI Co., LLC plans to sell an additional 20 shares of Class A Common Stock at $44.28.
• All reported sales are planned to be effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC on May 30, 2025.
• After these planned transactions, BFI Co., LLC's indirect beneficial ownership of Class A Common Stock will be 49,680 shares, and Class B Common Stock will be 19,991,034 shares.
• Jack Bendheim directly holds 16,840 shares of Class A Common Stock, which are not part of these planned transactions.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the planned reduction in insider ownership by the CEO and a significant shareholder. While the sales are pre-planned under a 10b5-1 plan, mitigating concerns about opportunistic trading, they still indicate an intent to divest a portion of holdings.

Negatives

• The planned sales by the President and CEO, who is also a 10% owner, represent a reduction in insider holdings, which can sometimes be interpreted negatively by the market.

Future Outlook

NA

Industry Context

This filing reports planned insider transactions and does not directly relate to broader industry trends or competitive landscape, other than reflecting a decision by a key executive in the animal health sector regarding personal equity holdings.

Related Party Transactions

• The transactions involve Jack Bendheim, President and CEO, Director, and 10% Owner, and BFI Co., LLC, a 10% owner over which Mr. Bendheim exercises voting and dispositive power. These are considered related party transactions for reporting purposes.

Stakeholder Impact

• Shareholders may view the planned insider sales as a signal of reduced confidence or a desire for diversification by a key executive and significant owner, potentially leading to negative sentiment.
• The existence of a 10b5-1 plan provides transparency and indicates that the sales are not based on new, non-public information, which may mitigate some shareholder concerns.

Key Dates

Recommendation

While the planned sales by the CEO and a significant shareholder are generally viewed as a negative signal, the fact that they are pre-arranged under a Rule 10b5-1 plan suggests they are not based on new, adverse material information. This filing alone does not provide sufficient new information to warrant a strong 'buy' or 'sell' recommendation, but it does indicate a reduction in insider ownership, supporting a 'hold' stance for investors to monitor future developments.

Keywords

Phibro Animal Health Corp, PAHC, Jack Bendheim, Insider Trading, Form 4, Stock Sales, 10b5-1 Plan, Class A Common Stock, Class B Common Stock, BFI Co., LLC